TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extubation Readiness Study in Very Low Birthweight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birthweight \>500g and\<1500g.~* Postmenstrual age \<34 weeks~* Mechanically ventilated \>48 hours~* Never successfully extubated~Exclusion Criteria:~* Congenital heart disease (other than patent ductus arteriosus (PDA), patent foramen ovale (PFO), and restrictive ventricular septal defect (VSD)~* Known or suspected airway anomalies~* Severe congenital malformations~* Need to remain intubated for other reasons (i.e. having surgery)~* Has met SBT criteria on previous calendar day (after 48 hrs of ventilation, PIP≤18, PEEP≤6, FiO2≤40%, Rate≤30, PS≤8)

- Gender: ALL
- Minimum Age: 48 Hours
- Maximum Age: 14 Weeks
- Healthy Volunteers: f

Study Arms:
- Spontaneous breathing trial (Type: EXPERIMENTAL): The spontaneous breathing trial will determine the extubation readiness of the subject.
- Usual care (Type: NO_INTERVENTION): Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have pathologically confirmed recurrence (reappearance of previously cleared) squamous cell cancer primary in the upper aerodigestive tract .Patients may have experienced more than one recurrence as long as the first recurrence occurred ≥ 6 months following the end of the prior RT.~2. The recurrence must have defined bi- or uni-dimensional measurements.~3. Recurrence must be confined to the head and neck above the clavicles (loco-regional recurrence).~4. The patient must not be a candidate for surgical resection.~5. Patients must be at least 6 months from completion of prior chemotherapy and radiation therapy.~6. Patients may have received prior chemotherapy as a component of their primary treatment, but not for recurrent disease.~7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~8. Granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum bilirubin ≤ 1.5 mg/dl, creatinine \< 1.5 mg/dl within 3 weeks prior to registration.~9. Liver Function Tests (LFTs) ≤ 2 x normal (serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic-pyruvic transaminase (SGPT)/Alkaline Phosphatase). If \> 2 x normal, liver ultrasound or CT is required to exclude metastases. If negative for metastases, patients are eligible.~10. Patients must sign a study-specific informed consent form prior to study entry.~Exclusion Criteria:~1. Distant metastases outside of the head and neck.~2. Primary disease in the nasopharynx or the salivary gland.~3. Other concurrent invasive malignancies.~4. Prior invasive malignancy unless disease free for at least two years (except prior in situ malignancies, e.g. cervix, breast, non-melanomatous skin cancer, etc. are permissible).~5. Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival.~6. Pre-existing grade ≥ 2 peripheral sensory neuropathy~7. Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns.~8. Prior history of sever hypersensitivity reaction to Docetaxol, Cetuximab or a drug with formulated with Polysorbate 80.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erbitux, Taxotere, LD Fractionated RT (Type: EXPERIMENTAL): Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact Analysis of Prognostic Stratification for Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with objectively diagnosed PE, both suspected or unsuspected (e.g. during CT for cancer staging and/or follow-up)~* Age \> 18 years~* Signature of written informed consent~Exclusion Criteria:~* Children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PESI score (Type: EXPERIMENTAL): treating physicians must formally calculate PESI and report in the clinical record form\* each day of hospitalization on top of routine clinical practice (standard care)
- Standard care (Type: NO_INTERVENTION): standard care (i.e. no formally calculation of PESI on top)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Physiotherapy Plus Non-invasive Brain Stimulation Improve Motor Recovery in Children With Acquired Brain Injury?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* sustained a cerebral stroke (ischaemic or haemorrhage) or TBI within the last three months;~* admitted to Holland Bloorview for intensive brain injury rehabilitation in the in/day patient programs;~* medically stable, as determined by their primary physician at Holland Bloorview;~* receiving active motor learning-based physiotherapy intervention four to five times per week, as prescribed by their treating PT;~* tolerate approximately 45 minutes of physiotherapy intervention;~* able to sit at the edge of the bed independently for 5s~* capable of participating in standardized physiotherapy assessment, from a cognitive and behavioural perspective, and;~* able to communicate discomfort (verbally or non-verbally).~Exclusion Criteria:~* primary injury of the cerebellum~* pre-existing seizure disorder (i.e., prior to ABI);~* anti-seizure medication not optimized at the time of study enrollment (i.e., physician is actively adjusting type or dose of anti-seizure medication)~* brain tumour;~* metal implants in the head;~* cranial bone flap removed;~* stitches/staples or open wound on the head;~* experience with tDCS in the last two years (as knowledge of the sensation of active tDCS will affect blinding of treatment groups);~* diagnosed with another neurological disorder(s) affecting gross motor function (e.g., cerebral palsy, spinal cord injury, guillain-barre syndrome, etc...);~* requires more than 15 minutes per physiotherapy treatment session of non-motor learning content (e.g., behavioural redirection, craniosacral therapy, vestibular therapy, passive range of motion)~* lower extremity weight bearing activity restrictions secondary to injuries (e.g., fracture, ligamentous injury)(at the time of study enrollment)~* non-orthopaedic physical activity restrictions secondary to other injuries (e.g., splenic laceration)~* balances on most affected leg for greater than 5s~* enrolment in another treatment-based research study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Physio+tDCS (Type: EXPERIMENTAL): Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
- Physio+sham (Type: SHAM_COMPARATOR): Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of CLL requiring treatment~* Refractory or relapsed disease~* Prior treatment with fludarabine~* Male or Female~* \>18 years of age~Exclusion Criteria:~* Treatment with rituximab within 90 days and alemtuzumab or any monoclonal antibody within 6 months.~* Clinically significant cardiac dysfunction or other significant organ dysfunction~Additional eligibility criteria apply that will be reviewed with potential study subjects at the site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCD122 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-65 years old~* AHI \>= 15~* BMI \< 35~Exclusion Criteria:~* Known cardiovascular disease, including hypertension~* Diabetes~* Acute or unstable chronic disease~* Renal failure~* Major organ system failure, including liver, renal, cardiac and respiratory failure~* Taking long-term medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- no treatment (Type: NO_INTERVENTION): being observed at 4 weeks and 12 weeks
- CPAP treatment (Type: ACTIVE_COMPARATOR): a machine delivers positive airway pressure into the upper airway via nasal mask

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Metastatic disease~* Documented disease progression~  * Must have received and subsequently failed (due to disease progression) ≥ 2 prior sequential endocrine therapies for treatment of metastatic breast cancer~    * Disease progression during adjuvant tamoxifen is considered 1 prior therapy~   * The 2 most recent treatments must have been endocrine agents~* At least 1 objective measurable disease parameter~* Brain metastases allowed provided both of the following criteria are met:~  * Brain metastases were previously treated AND are currently stable~ * Brain metastases are not the only site of metastatic disease~* Hormone receptor status~  * Estrogen and/or progesterone receptor-positive tumor~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Postmenopausal, as defined by any of the following:~  * At least 50 years of age with an intact uterus AND amenorrheic for the past 12 months~ * At least 50 years of age without a uterus AND follicle-stimulating hormone (FSH) level within postmenopausal range~ * Under 50 years of age and FSH level within postmenopausal range~ * Prior bilateral oophorectomy~Performance status~* ECOG 0-2~Life expectancy~* At least 6 months~Hematopoietic~* Adequate hematologic function~Hepatic~* Adequate hepatic function~* Bilirubin ≤ 1.5 times upper limit of normal~* No history of hepatic adenoma~Renal~* Adequate renal function~* No history of hypercalcemia or severe hypocalcemia~Cardiovascular~* No history of thrombophlebitis or thromboembolic disorders associated with prior estrogen use~* No active thrombophlebitis or thromboembolic disorders~* No history of uncontrolled hypertension~Other~* Not pregnant~* No undiagnosed abnormal vaginal bleeding~* No other serious medical illness~* No psychiatric illness that would preclude giving informed consent~* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Prior chemotherapy for metastatic disease allowed~* Prior adjuvant chemotherapy allowed~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* Prior radiotherapy allowed provided the only site of measurable disease was not irradiated~Surgery~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A pathologically (histological or cytological) confirmed clinical diagnosis of non-small cell lung cancer (NSCLC) or GI cancer~2. Stage 3 or 4 disease and eligible for anti-cancer treatment~3. Performance status (PS) of 0 - 2 as determined by the Eastern Cooperative Oncology Group-Performance Status~4. Life expectancy estimated at \> 4 months~5. Age 18 years or older~6. Willing and able to provide informed consent~7. Must be approved for participation by the oncology treatment team~8. Able to communicate in French or English~Exclusion Criteria:~1. Contraindication to exercise as determined by the oncology treatment team~2. Severe cardiac or neuro-muscular/skeletal disease~3. Engaging in interventions to address anxiety or depressive symptoms~4. Brain metastases~5. Active psychiatric conditions~6. Pregnant or breast-feeding mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Exercise (Type: ACTIVE_COMPARATOR): See methods below - standard strength and endurance training
- Qigong exercise (Type: EXPERIMENTAL): See methods below - medical QiGong therapy session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Recurrent Urinary Tract Infections With α-D-mannose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* ≥ 3 UTIs within the last 12 months or ≥ 2 UTIs within the last 6 months;~* Laboratory urine culture: \<103 CFUs~* Age \> 18 years~Exclusion Criteria:~* UTIs ≥ 12 within 1 year~* Pregnancy or Lactation~* Immune disease~* Lactose intolerance~* Urinary tract anomaly~* Systemic infection~* Newly started hormone therapy within the last 6 months~* Antibiotic prophylaxis within the last 6 months~* α-D-mannose intake within the last month~* Use of catheters~* Diabetes mellitus~* Participation to other studies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mannose (Type: EXPERIMENTAL): 2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary
- placebo (Type: PLACEBO_COMPARATOR): 2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* English speaking~* creation of new ileostomy~* access to smartphone with bluetooth technology to support OIA application~* able to give written consent~* have preoperative counseling about stoma with ostomy nurse (excludes emergent ostomy creation)~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ostom-i device (Type: EXPERIMENTAL): Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria include:~* Clinical diagnosis of advanced heterogeneous emphysema~* Age \> 18 years at the time of initial presentation~* Clinically significant dyspnea (MRC Dyspnea \>/= 2)~* Failure of standard medical therapy to provide relief of symptoms~* BUN, creatinine, ALT, AST, alkaline phosphatase, WBC, hematocrit, platelet count, PT and PTT within normal limits~* Pulmonary function tests~Exclusion Criteria:~* Alpha-1 protease inhibitor deficiency verified by a serum level of \< 80 mg% or knowledge of PI\*ZZ genotype~* Body mass index \< 15 kg/m2 or \> 35 kg/m2~* Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis~* Tobacco use within 16 weeks of the initial clinic visit~* Allergy to fish or pork products or sensitivity to tetracycline~* FEV1 \<20% with DLCO \<20% or homogeneous disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single (Type: EXPERIMENTAL): BLVR treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk patients - Two to three of the following: PSA 10-30 ng/mL, Gleason score greater than or equal to 6, clinical stage greater than or equal to T2c (2002 ACJJ).~* CT of the abdomen and pelvis and bone scan without evidence of metastases.~* An enzymatic prostatic acid phosphatase must be obtained prior to randomization.~* A serum testosterone must be obtained prior to initiation of androgen deprivation therapy.~* No prior pelvic external beam radiation therapy for prostate cancer or other malignancies.~* No prior androgen deprivation therapy.~* Minimum 5 year life expectancy.~* No other invasive cancer diagnosis other than non-melanoma skin cancer within the last 5 years.~Exclusion Criteria:~* Exclusion criteria will be limited to patients who do not meet the above eligibility criteria.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- no hormones (Type: ACTIVE_COMPARATOR): All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
- 9 months of hormone therapy (Type: ACTIVE_COMPARATOR): All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Types of Pain Relief After Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled cesarean section performed under spinal anesthesia~* ASA I or II~* height above 1,55 m~* singleton pregnancy~Exclusion Criteria:~* contre indication to a drug used in the study (levobupivacaine, ketoprofen, nefopam)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Transversus Abdominis Plane (TAP) Block (Type: EXPERIMENTAL): Patients will receive a bilateral transversus abdominis plane block
- Incisional Infiltration of Local Anesthetic (Type: ACTIVE_COMPARATOR): Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility